Avoro Capital Advisors LLC Takes Position in GH Research PLC $GHRS

Avoro Capital Advisors LLC bought a new stake in GH Research PLC (NASDAQ:GHRS) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,800,000 shares of the company’s stock, valued at approximately $22,860,000. Avoro Capital Advisors LLC owned about 3.46% of GH Research at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Barclays PLC lifted its stake in shares of GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after acquiring an additional 822 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after acquiring an additional 2,400 shares during the last quarter. Jefferies Financial Group Inc. lifted its stake in shares of GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after acquiring an additional 2,988 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of GH Research in the 4th quarter valued at about $38,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of GH Research in the 2nd quarter valued at about $79,000. Institutional investors own 56.90% of the company’s stock.

GH Research Stock Down 1.9%

GHRS opened at $19.98 on Wednesday. The stock has a market cap of $1.37 billion, a PE ratio of -21.72 and a beta of 1.31. The business has a 50 day moving average of $20.43 and a 200-day moving average of $16.80. GH Research PLC has a 52 week low of $11.32 and a 52 week high of $25.94.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Equities analysts anticipate that GH Research PLC will post -1.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on GHRS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research report on Tuesday, April 21st. Citigroup reaffirmed an “outperform” rating on shares of GH Research in a research report on Friday, May 15th. HC Wainwright lowered their price target on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Citizens Jmp lowered their price target on GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a research report on Friday, May 15th. Finally, Guggenheim set a $34.00 price target on GH Research and gave the company a “buy” rating in a research report on Tuesday, March 10th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, GH Research presently has an average rating of “Moderate Buy” and a consensus price target of $40.38.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.